Matthew Biegler
Stock Analyst at Oppenheimer
(2.76)
# 2,877
Out of 5,182 analysts
91
Total ratings
36.59%
Success rate
0.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $36.69 | +36.28% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $747.36 | +15.74% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $16.80 | -16.67% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $16.63 | +188.64% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $25.65 | +75.44% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $10.63 | +41.11% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $9.46 | +132.56% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $16.44 | +70.32% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.76 | +354.55% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.76 | +47.06% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.32 | +287.93% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $15.17 | +954.71% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $10.62 | +323.73% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $133.29 | -13.72% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $31.83 | +66.51% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $3.99 | +401.25% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.96 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.53 | +85.92% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.18 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.35 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $21.49 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.32 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.22 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $36.69
Upside: +36.28%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $747.36
Upside: +15.74%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $16.80
Upside: -16.67%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $16.63
Upside: +188.64%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $25.65
Upside: +75.44%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $10.63
Upside: +41.11%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $9.46
Upside: +132.56%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $16.44
Upside: +70.32%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.76
Upside: +354.55%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.76
Upside: +47.06%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.32
Upside: +287.93%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $15.17
Upside: +954.71%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $10.62
Upside: +323.73%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $133.29
Upside: -13.72%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $31.83
Upside: +66.51%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.99
Upside: +401.25%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.96
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.53
Upside: +85.92%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.18
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.35
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $21.49
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.32
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.22
Upside: -